On January 20, 2022, the Rare Disease Legislative Advocates (RDLA) hosted its first monthly webinar for 2022. In this month's program, the speakers provided an overview of the progress that…
An article in PubMed dated October 8, 2021 outlines immune therapies treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) patients. Both cancers are hematologic malignancies that begin in the…
According to a recent article, new evidence shows adding ibrutinib to a patient’s chemotherapy regimen may improve the longevity of younger patients with diffuse large B-cell lymphoma (DLBCL). Diffuse Large…
Glioblastoma is a highly malignant and aggressive brain cancer. With a 5-year survival rate of under 10%, there is an urgent need for newer and more effective diagnostic and treatment…
According to a recent article, the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition displayed the advances that have been made in the management of follicular lymphoma. Follicular…
We have been living in the midst of a pandemic for years now, and with that has come a number of lasting effects. One of these effects, which has been…
According to a recent article, patients diagnosed with minimal change disease are found to have autoantibodies targeting nephrin, which supports previous research. Minimal Change Disease (MCD) Minimal change disease is…
Over the last few years, more research has been dedicated to understanding the impact of gut health and the gut microbiome on overall health. More recently, researchers sought to understand…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
